Joseph Alvarnas, MD, vice president of government affairs, City of Hope, and chief clinical advisor, AccessHope, Duarte, California, discusses potential payer biases against experimental or investigational clinical trials and the payer’s role in trial diversity.
Alvarnas served as cochair for the 11th Annual Patient-Centered Oncology Care® (PCOC) meeting, presented by The American Journal of Managed Care® November 9-10, 2022, in Nashville, Tennessee. He spoke with Evidence-Based Oncology™ (EBO) about a panel discussion he chaired on improving diversity in clinical trials.
EBO: What are some common payer barriers for participating in clinical trials?
Alvarnas: Some of the challenges historically have been related to this idea of something being experimental or investigational. The idea that you should pay for care that is an established standard or that represents best practice is something that both payers and clinicians have embraced. What makes cancer care different is that, for a significant percentage of patients that we serve, optimal care has yet to be identified—or we have therapies that may work very well, but [with associated] toxicities are not what we would want.
I think context is really important, and if we can engage payers in a discussion as to the value of a clinical trial—a well-designed, very appropriately constructed clinical trial that can actually answer specific clinical questions and potentially deliver value to patients—then I think we can reset this idea that experimental and investigational represents some irresponsible practice of medicine. For many patients in the cancer care domain, it represents the top choice for best practice.
EBO: Why do payers have a stake in greater diversity in clinical trials?
Alvarnas: [W]e’re living in a nation that’s becoming increasingly diverse, and there are 2 challenges in that increasing diversity. The first is we want to make sure that our health care system is appropriately patient-centered, and if you can’t respect or integrate that level of emerging and growing diversity into how we deliver care, then you’ve already created a system that’s not very good at delivering care to diverse populations or to the nation as a whole.
The other aspect of this is we don’t know what we don’t know. The beauty of clinical trials is we can identify new knowledge and new knowledge that’s hopefully applicable to either an entire population or to subsets within that population. In the realm of knowing to what extent clinical trial findings are generalizable, we have to diversify who’s enrolled in that trial, because we’re not all biologically identical, and not all people are superimposable. So, if we can better understand the applicability of a clinical trial and the generalizability of those results, then it helps us to empower better decision-making after that trial is complete.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More